RNA Therapeutics Market - By Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference Therapeutics, siRNA Therapeutics), Indication (Infectious Diseases, Autoimmune Disorders), End-use (Hospitals, Research Institutes), Global Forecast, 2024 -

RNA Therapeutics Market - By Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference Therapeutics, siRNA Therapeutics), Indication (Infectious Diseases, Autoimmune Disorders), End-use (Hospitals, Research Institutes), Global Forecast, 2024 - 2032

RNA therapeutics market size is set to record 5.7% CAGR of between 2024 and 2032, driven by the increasing prevalence of chronic disorders, such as cancer, genetic disorders, and infectious diseases. As per National Institutes of Health (NIH), in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the U.S. RNA therapeutics offer the potential to address these diseases by targeting specific genes and pathways for providing more effective and personalized treatment approaches. Advancements in RNA delivery technologies, such as lipid nanoparticles and viral vectors, are enhancing the efficacy and safety profile of RNA-based drugs.

Moreover, the regulatory landscape surrounding RNA therapeutics is evolving, with regulatory agencies increasingly recognizing the potential of RNA-based drugs for streamlining the approval process. The growing adoption of personalized medicine approaches, driven by advancements in genomic sequencing and molecular diagnostics is also creating opportunities for RNA therapeutics to target specific patient populations with precision. As healthcare systems worldwide strive to improve patient outcomes and reduce healthcare costs, the demand for innovative and targeted therapies is expected to bolster the industry growth.

The RNA therapeutics market is classified on the basis of product, type, indication, end-use and region.

Based on indication, the industry size from the autoimmune disorder segment is slated to record a 6% CAGR through 2032, characterized by dysregulated immune responses targeting the body's own tissues. RNA therapeutics offer a promising avenue for treating autoimmune diseases by targeting specific molecular pathways involved in immune dysregulation. Additionally, advancements in RNA-based technologies, such as antisense oligonucleotides and small interfering RNAs, enable precise modulation of gene expression associated with autoimmune disorders, thereby offering potential therapeutic benefits.

In terms of end-use, the RNA therapeutics market from the academic & research institutes segment is anticipated to observe a 5.4% CAGR during 2024 and 2032. This is driven by advancements in the understanding of RNA biology for uncovering novel therapeutic targets and developing innovative RNA-based therapies. Moreover, academic and research institutes serve as incubators for talent and innovation for nurturing the next generation of scientists and entrepreneurs, further propelling the segment growth.

Asia Pacific RNA therapeutics industry will grow substantially at 6.1% CAGR between 2024 and 2032, attributed to the large and diverse population coupled with the high prevalence of infectious and chronic diseases. The presence of a robust biotechnology ecosystem, characterized by a network of academic research institutions, biopharmaceutical companies, and government initiatives is fostering multiple R&D activities in RNA therapeutics. Furthermore, favorable regulatory policies and increasing investments in healthcare infrastructure and biotechnology will stimulate the regional industry growth.

Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculation
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary Paid sources Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers Rising incidence of infectious diseases Advancements in RNA delivery technologies Increasing partnerships and collaborations among market players
3.2.2 Industry pitfalls & challenges Recall of RNA therapeutic products High cost of development and manufacturing
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)
5.1 Key trends
5.2 Vaccines
5.3 Drugs
Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)
6.1 Key trends
6.2 mRNA therapeutics
6.3 Antisense oligonucleotide (ASO) therapeutics
6.4 siRNA (small interfering RNA) therapeutics
6.5 RNA interference (RNAi) therapeutics
6.6 Other types
Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)
7.1 Key trends
7.2 Infectious diseases
7.3 Hereditary/genetic diseases
7.4 Autoimmune disorders
7.5 Other indications
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
8.1 Hospitals
8.1.1 Private
8.1.2 Public
8.2 Academic & research institutes
8.3 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alnylam Pharmaceuticals, Inc.
10.2 Arrowhead Pharmaceuticals, Inc.
10.3 BioNTech SE
10.4 Ionis Pharmaceuticals
10.5 Moderna Inc.
10.6 Novartis AG
10.7 Orna Therapeutics, Inc.
10.8 Pfizer Inc.
10.9 Sanofi
10.10 Sarepta Therapeutics, Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings